Citations

Clear

65 citation(s) found for "Spinelli, A".

Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ ‐1 Study Eligibility: A Large Global Analysis in a Real‐World Setting
Prinzi, Federica Lo , Rimini, Margherita , Ikeda, Masafumi, Antonuzzo, Lorenzo, Kim, Jin Won, Pressiani, Tiziana, Peeters, Frederik , Pinato, David J., Pircher, Chiara, Tamberi, Stefano, Couto, Nuno, Chon, Hong Jae, Martirena, A. , Lamarca, Angela, Perkhofer, Lukas , Kim, Il Hwan, Pinto, C. , Kang, Beodeul, Pastorino, Alessandro , Changhoon, Yoo, Rodriquenz, Maria Grazia , Scartozzi, Mario, Zumstein, Lucrezia , Ghidini, Michele, Aprile, Giuseppe , Spinelli, Gian Paolo , Yung‐Yeh, Su, Warmington, Emily , Lancianese, Alessia , Satake, Tomoyuki, Bekaii‐Saab, Tanios, Lavacchi, Daniele, Passeri, Laura , Kang, Minsu, Prete, Alessandra Anna, Bozzarelli, Silvia, Persano, Mara , Masi, Gianluca, Balsano, Rita , Lonardi, Sara, Salani, Francesca, Camera, Silvia, Vogel, Arndt, Rimassa, Lorenza, Rimassa, Lorenza , Vivaldi, Caterina , Farinea, Giovanni , Prager, Gerald W , Chan, Stephen L , Niger, Monica , Fornaro, Lorenzo , Casadei-Gardini, Andrea , Lo Prinzi, Federica , Rimassa, Lorenza , Saborowski, Anna , Rimini, Margherita , Ikeda, Masafumi , Abidoye, Oluseyi , Lucchetti, Jessica , Antonuzzo, Lorenzo , Kim, Jin Won , Nichetti, Federico , Pressiani, Tiziana , Vivaldi, Caterina , Rapposelli, Ilario Giovanni , Braconi, Chiara , Pinato, David J. , Tamburini, Emiliano , Pircher, Chiara , Tamberi, Stefano , Castet, Florian , Verrico, Monica , Parisi, Alessandro , Couto, Nuno, Chon, Hong Jae , Lamarca, Angela , Landriscina, Matteo , Finkelmeier, Fabian , Oneda, Ester , Avallone, Antonio , Dell’Aquila, Emanuela , Kim, Il Hwan, Formica, Vincenzo , Garajova, Ingrid , Kang, Beodeul , Corallo, Salvatore , Fenocchio, Elisabetta , Diana, Anna , Schirripa, Marta , Scartozzi, Mario , Ghidini, Michele , Prager, Gerald W. , Chan, Stephen L. , Warmington, Emily, Satake, Tomoyuki , Bekaii‐Saab, Tanios , Giordano, Guido , Ferrara, Michele , Kang, Minsu, Prete, Alessandra Anna , Bozzarelli, Silvia , Masi, Gianluca , Niger, Monica , Lonardi, Sara , Salani, Francesca , Camera, Silvia , Vogel, Arndt , Fornaro, Lorenzo , Casadei‐Gardini, Andrea

Mayo Clinic

International Journal of Cancer | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ijc.70699 | PMID 42581755 Get It

ABSTRACT Many real‐world patients with advanced biliary tract cancer (BTC) are excluded by TOPAZ‐1 criteria; this study assessed cisplatin and gemcitabine plus durvalumab (CGD) efficacy and safety in these patients. Data from 1358 patients with advanced BTC treated with first‐line CGD across 55 international centers were retrospectively analyzed. Patients were classified as TOPAZ‐1‐in (meeting all inclusion criteria) or TOPAZ‐1‐out (meeting ≥ 1 exclusion criterion). Primary endpoints were overall survival (OS) and progression‐free survival (PFS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and safety. Furthermore, OS and PFS of the TOPAZ‐1‐out cohort were compared with reconstructed survival data from the phase III trial. 912 (67.1%) patients were classified as TOPAZ‐1‐in , and 446 (32.9%) as TOPAZ‐1‐out . After a median follow‐up of 14.5 months (95% CI: 13.7–36.5), OS was 16.1 months in TOPAZ‐1‐in and 12.5 months in TOPAZ‐1‐out (HR 0.69, 95% CI: 14.6–16.5, p = 0.0001); PFS was 8.2 versus 6.5 months (HR 0.73, 95% CI: 7.1–8.1, p < 0.0001). Median OS in the TOPAZ‐1‐out cohort (12.5 months) was nearly identical to the phase III trial experimental arm (12.9 months; HR 1.15, p = 0.13); for PFS the HR was 1.12 (95% CI 0.93–1.42; p = 0.09). Among TOPAZ‐1‐out patients, active infection, elevated bilirubin, and ECOG PS > 1 were linked to poorer OS, while no detrimental impact emerged for ALT/AST abnormalities, corticosteroid use, renal or hematologic parameters, or prior surgery within 6 months, suggesting treatment effectiveness was broadly maintained across clinical subgroups. Furthermore, TOPAZ‐1‐out patients experienced no significant increase in adverse events compared with the TOPAZ‐1‐in group. Real‐world data suggest CGD may be effective in TOPAZ‐1‐out patients, with no evident increase in toxicity, supporting the potential expanded use of the regimen in clinical practice.
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real‐World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab
Rimini, Margherita , Lamarca, Angela, Ikeda, Masafumi, Kim, Jin Won , Vogel, Arndt, Peeters, Frederik , Pinato, David J., Pircher, Chiara, Martirena, A. , Perkhofer, Lukas , Pinto, C. , Kang, Beodeul, Pastorino, Alessandro , Changhoon, Yoo, Rodriquenz, Maria Grazia , Scartozzi, Mario, Zumstein, Lucrezia , Ghidini, Michele, Aprile, Giuseppe , Spinelli, Gian Paolo , Yung‐Yeh, Su, Bolnykh, Iakov, Lancianese, Alessia , Satake, Tomoyuki, Lavacchi, Daniele, Passeri, Laura , Kang, Minsu, Viola, Massimo, Persano, Mara , Balsano, Rita , Ratti, Francesca, Rimassa, Lorenza , Kim, Jin Won , Vivaldi, Caterina , Formica, Vincenzo , Farinea, Giovanni , Prager, Gerald W , Chan, Stephen L , Niger, Monica , Fornaro, Lorenzo , Casadei-Gardini, Andrea , Rimassa, Lorenza , Saborowski, Anna , Rimini, Margherita , Lamarca, Angela , Ikeda, Masafumi , Abidoye, Oluseyi , Lucchetti, Jessica , Antonuzzo, Lorenzo , Vogel, Arndt , Nichetti, Federico , Pressiani, Tiziana , Vivaldi, Caterina , Rapposelli, Ilario Giovanni , Braconi, Chiara , Pinato, David J. , Tamburini, Emiliano , Pircher, Chiara , Tamberi, Stefano , Castet, Florian , Verrico, Monica , Parisi, Alessandro , Couto, Nuno , Chon, Hong Jae , Landriscina, Matteo , Finkelmeier, Fabian , Oneda, Ester , Avallone, Antonio , Dell’Aquila, Emanuela , Kim, Il Hwan , Garajova, Ingrid , Kang, Beodeul , Corallo, Salvatore , Fenocchio, Elisabetta , Diana, Anna , Schirripa, Marta , Scartozzi, Mario , Ghidini, Michele , Prager, Gerald W. , Chan, Stephen L. , Bekaii‐Saab, Tanios , Ferrara, Michele , Kang, Minsu, Bozzarelli, Silvia , Masi, Gianluca , Niger, Monica , Lonardi, Sara , Salani, Francesca , Camera, Silvia , Ratti, Francesca , Fornaro, Lorenzo , Casadei‐Gardini, Andrea

Mayo Clinic

International Journal of Cancer | July 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ijc.70641 | PMID 42524843 Get It

ABSTRACT Surgery after response to first‐line chemoimmunotherapy may offer a potential curative option for patients with locally advanced biliary tract cancer (BTC) initially considered unresectable. However, robust real‐world evidence in this setting remains limited. We retrospectively analyzed patients with locally advanced BTC treated with first‐line cisplatin, gemcitabine, and durvalumab (CGD) across 55 centers in 12 countries. Endpoints included overall survival (OS), progression‐free survival (PFS), disease‐free survival (DFS) among resected patients, objective response rate (ORR), and the prognostic impact of surgery. A multivariable logistic regression model was developed to predict surgical conversion using baseline clinical and laboratory variables. Among 1358 screened patients, 219 had locally advanced disease and were included in the analysis. Median follow‐up was 14.5 months. ORR was 34.6%, with median PFS and OS of 10.0 and 20.7 months, respectively. Twenty‐four patients (10.9%) underwent surgical resection after systemic therapy. Median OS was 22.5 months in resected patients versus 19.9 months in those who did not undergo surgery. Median DFS after resection was 15.8 months. Pathological lymph node involvement was independently associated with shorter DFS. Larger baseline tumor size correlated with higher odds of radiological response but not with OS. An exploratory elastic‐net model retained four baseline variables and showed moderate discriminative ability for surgical conversion, with an apparent AUC of 0.72 and an optimism‐corrected AUC of 0.65. First‐line CGD enabled secondary resection in approximately 11% of patients with locally advanced BTC. A simple baseline model may support patient selection for conversion surgery, although prospective validation is needed.
Development of a standard definition of ‘no-option’ and ‘poor-option’ for revascularization in chronic limb-threatening ischemia
Fabiani, Mario Alejandro , Berg, Jos C van den, Torre, Oscar A De la, Verastegui, Alfredo , Dua, Anahita, Alexandrescu, Vlad Adrian, Baadh, Amanjit S. , Bahaa, Nasr, Carvajal, Juan Guillermo Barrera, Beasley, Robert , Bisdas, Theodosios, Blessing, Erwin , Bonvini, Stefano, Brodmann, Marianne, Cabral, Gonçalo, Cancellieri, Roberto, Casini, Andrea , Chandra, Venita , Chisci, Emiliano, Chohan, Omar, Choke, Edward, Chong, Patrick, Clerici, Giacomo , Coscas, Raphaël, Costantino, Del Giudice, D'Oria, Mario, Davies, Robert, Donato, Gianmarco de , Vries, Jean-Paul de , Río-Solá, M.L. del, Deloose, Koen , Dhand, Sabeen , Díaz-Sandoval, Larry J, Falcone, Gianmarco , Fanelli, Fabrizio , Cardona, Lucas Ferrer, Garg, Karan, Giuffrida, Stefania, Gouëffic, Yann, Goverde, Peter , Henao, Esteban, Vegas, Diego Jorge Herrera, Hinchliffe, Robert, Hoballah, Jamal J. , Howard, Dominic, Huasen, Bella , Iida, Osamu, Katsanos, Konstantinos, Kolh, Philippe, Korosoglou, Grigorios, Lecis, Alexandre, Leopoldo, Marine, Lessne, Mark L. , Lichtenberg, Michael, Lobato, Marta , Loreni, Giorgio, Madassery, Kumar, Manzi, Marco, Maene, Lieven, Maresch, Martin, Trabal, Jorge Martinez, Mathews, S Jay, Michael, Siah, J, Bosiers Michel, Migliara, Bruno , Mills, Joseph, Miserlis, Dimitrios , Montero-Baker, Miguel, Alvarez, Luis Morelli, Morgan, Robert Anthony, Mouawad, Nicolas, Moxey, Paul, Antonio, Jose, Nakama, Tatsuya , Neville, Richard, Noronen, Katariina , Palena, Mariano, Parikh, Sahil, Parlani, Gianbattista, Pasqui, Edoardo , Patel, Rafiuddin, Patel, Ashish, Perkov, Dražen , Portou, Mark James, Langhoff, Ralf , Reijnen, Michel Marinus Petrus Johannes, Roy, Trisha , Ruffino, Maria Antonella , Gúzman, Tania Sáez, Sakr, Ahmed, Santini-Domínguez, Rafael , Schmidt, Andrej, Schneider, Peter, Sheorain, Virendersingh K, Siracuse, Jeffrey, Sirvent, Marc , Sommerset, Jill , Spiliopoulos, Stavros, Spinelli, Alessio , Stavroulakis, Konstantinos, Taneva, Gergana T, Teso, Desarom , Thomas, Shannon, Torsello, Giovanni, Tummala, Venkat, Tummala, Srinivas, Twine, Christopher, Uberoi, Raman, Heuvel, Daniel Van den, Varcoe, Ramon Lee, Serrano, José Francisco Vargas, Céniga, Melina Vega de, Venermo, Maarit, Vijaynagar, Badri, Stempel, Conrad von , Voûte, Michiel Thomas, Watts, Mine, Zaefferer, Patricio, Zayed, Hany , Zeebregts, Clark J, Zola, N'Dandu, Mills, Joseph L. , Torre, O. , Verastegui, Alfredo , de la Torre, Oscar , Fabiani, Mario Alejandro , Berg, Jos C. van den , Dua, Anahita , Nasr, Bahaa , Biasi, Lukla , Bisdas, Theodosios , Brodmann, Marianne , Cabral, Gonçalo , Caradu, Caroline , Casini, Andrea , Chisci, Emiliano , Choke, E, Chong, Patrick L.E., Cioppa, Angelo , Coscas, Raphaël , Giudice, Costantino Del , D'Oria, Mario , Peruyera, Pablo Del Canto , Διαμαντόπουλος, Αθανάσιος , Díaz‐Sandoval, Larry J. , Dick, Florian , Fazzini, Stefano , Ferrer, Lucas M. , Fujihara, Masahiko , Garg, Karan , Garriboli, Luca , Genovese, Elizabeth A. , Gifford, Edward D. , Gouëffic, Yann , Gupta, Prem Chand , Vegas, Diego Herrera , Hinchliffe, Robert J. , Holden, Andrew Hugh , Isernia, Giacomo , Kolh, Philippe H. , Korosoglou, Grigorios , Krokidis, Miltiadis E. , Lichtenberg, Michael, Loureiro, Luís , Mathews, S. Jay , Bosiers, Michel Joseph , Morosetti, Daniele , Mouawad, Nicolas J. , Moxey, Paul, Neville, Richard, Palena, Luis Mariano , Parikh, Sahil, Parlani, Gianbattista, Patel, Rafiuddin, Patrone, Lorenzo , Portou, Mark J. , Pratesi, Giovanni , Rammos, Christos , Reijnen, Michel M.P.J. , Sakr, Ahmed , Schneider, Peter A. , Secemsky, Eric A. , Sheorain, Virendersingh K, Simonte, Gioele , Spiliοpoulos, Stavros , Stavroulakis, Konstantinos , Steiner, Sabine , Taneva, Gergana T. , Torsello, Giovanni , Troisi, Nicola , Twine, Christopher P. , Uberoi, Raman , Ucci, Alessandro , Heuvel, Daniel van den, Varcoe, Ramon Lee , Venermo, Maarit A. , Voûte, Michiel T., Ysa, August , Zeebregts, Clark J. , Zeller, Thomas , N'Dandu, Zola M.

Mayo Clinic

British Journal of Surgery | April 3, 2026 | Volume: 113 | Issue: 4 | Pages: No page available

10.1093/bjs/znag040 | PMID 41941595 Get It

Abstract Introduction Revascularization to prevent limb loss is not feasible or represents a very high risk in a significant proportion of patients with chronic limb-threatening ischaemia (CLTI). No standard definition currently exists to define this population of patients. The aim of this study was to develop a consensus-based, multidomain definition to improve clinical assessment and reporting of studies in people with ‘no option’ (NO) or ‘poor option’ (PO) CLTI. Methods A modified Delphi process was conducted with 164 specialists from 30 countries. Two iterative survey rounds were used to reach consensus, defined as ≥70% agreement with a score of ≥7 on a nine-point scale. Results Some 164 international vascular specialists participated in the study, averaging 19 years of experience. A multidomain framework including arterial disease anatomy, biology, risk, function, and context (ABRFC) achieved 83% consensus. A ‘desert foot’ was defined as the absence of distal arterial revascularization targets on advanced non-invasive imaging, invasive digital subtraction angiography, and at least one failed endovascular revascularization attempt (81.6% agreement). Inadequate autogenous bypass conduit was defined as the lack of usable autologous vein across all four limbs (85% agreement). Patients were classified as NO for revascularization if they present with ‘desert foot’, prohibitive medical risk, a non-functional limb, or in those patients who refused arterial revascularization. PO revascularization patients combined factors such as severe infection, lack of autologous vein, or treatment non-compliance (72.1% agreement). Conclusion This consensus study established a structured, expert-validated definition of no option or poor option for revascularisation of patients with CLTI. The multidomain ABRFC framework provides a foundation for standardized clinical assessment, trial design, and future guideline development.
P0762 Defining Quality Pouch Surgery – A Critical Step Towards Centralization? International Consensus on Key Performance Indicators in Pouch Surgery (KPIPS) Study
Holubar, S, Soop, M., Poskus, T, Neary, P, Uchino, Tairin , Yang, S S, Adamina, M, Avellaneda, N L, Barnes, E, Brouquet, A, Brown, S R, Overstraeten, A De Buck Van, Buskens, C J, Chiorean, Michael , Clark, D, Cohen, B, Ouali, S El, Faiz, O D, Hahnloser, Dieter, Hancock, L, Herfarth, H, Johnston, M, Kayal, M, Laharie, D, Liberman, S, Loftus, E, Moeslein, G, Myrelid, P, Qazi, Taha , Raffals, L, Rubin, D T, Spinelli, A, Steinhagen, Emily , Verstock, Bram, Warusavitarne, J, Wexner, S, Winter, D, Group, KPIPS Study, Verstockt, Bram , Clark, David A. , Verstockt, B , Holubar, Stefan D. , Poškus, Tomas , Neary, Peter, Brouquet, Antoine , Overstraeten, Anthony de Buck van , Buskens, Christianne Johanna , Ouali, Sara El , Faiz, Omar , Fichera, Alessandro , Hahnloser, Dieter , Herfarth, Hans , Kayal, Maia , Laharie, David , Liberman, Sender A., Myrelid, Pär , Poylin, Vitaliy Y. , Raffals, Laura E. , Spinelli, A, Tozer, Phil J. , Wexner, Steven D

Mayo Clinic

Journal of Crohn’s and Colitis | January 21, 2026 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/ecco-jcc/jjaf231.943 Get It

Abstract Background Global data demonstrate an inverse relationship between hospital ileoanal pouch volume and adverse outcomes, highlighting the need for quality metrics for this technically demanding procedure.1-4 Currently, there are no standardised quality indicators to define high-quality pouch surgery. This study aimed to establish international consensus on key performance indicators (KPIs) in pouch surgery. Methods A modified Delphi process was conducted among an international, multidisciplinary panel of experts. Participants were identified through professional networks, literature review, and direct email invitation; additional participants recruited via a snowball sampling approach over one month. Candidate KPIs were generated from literature review and expert input across 5 domains. Each item was rated on a 9-point Likert scale (1 = not important, 9 = critically important); consensus was predefined as ≥ 80% of respondents rating an item 7–9. Items not reaching consensus were re-rated in a second round following anonymized group feedback. Results Round 1 included 312 participants from 37 countries. Demographics (Table 1): 53% were age 45 years, 35.2% were female, and included surgeons (68.6%) and gastroenterologists (31.1%). Most (76.6%) practice at academic or university hospitals, with a median of 11 (5–17) years in practise; 78.9% perform &gt;1 pouchoscopy per month, and 39.5% of surgeons perform 5 pouches/year. Respondents’ regions included North America (51%), Europe (26%), Oceania (9%), Asia (6%), Latin America (4%), and the Middle East/Africa (4%). Seven (18%) countries (Denmark, Lithuania, Malaysia, Norway, United Arab Emirates, Sweden, and Switzerland) reported pouch surgery is already centralised, while 70.6% agreed pouch centralisation should be implemented. Cost/logistics and professional autonomy were the most important barriers to centralisation, whereas capacity and training exposure were least important. Overall, 37/59 (62.7%) candidate KPIs reached consensus after Round 1. The Round 2 response rate was 61%, and 2 additional KPIs reached consensus (preop ileitis and long-term risk of pouchitis). Additionally, 14 of 25 (56%) informed consent items reached consensus, and 64% of respondents felt informed consent for pouch surgery requires 2 or more office visits. Consensus items were used to populate a KPIPS Checklist (Figure 1). Conclusion Through an international Delphi process, the KPIPS study identified a consensus-derived set of key performance indicators to measure quality in pouch surgery. These quality metrics provide a foundation for benchmarking outcomes and represent a critical step towards centralization and the development of designated pouch centres of excellence to improve global standards of care for pouch patients. References: 1. Worley GHT, Fearnhead NS, Brown SR, et al. Review of current practice and outcomes following ileoanal pouch surgery: Lessons learned from the ileoanal pouch registry and the 2017 ileoanal pouch report. Colorectal Dis 2018;20:913–22. 2. Giddings HL, Yang PF, Steffens D, Solomon MJ, Ng KS. Influence of hospital-level and surgeon factors on the outcomes after ileo-anal pouch surgery for inflammatory bowel disease: Systematic review. Br J Surg 2024;111. 3. Hoang CM, Maykel JA, Davids JS, et al. Distribution of elective ileal pouch-anal anastomosis cases for ulcerative colitis: A study utilizing the university health system consortium database. J Gastrointest Surg 2020;24:2613–9. 4. Moojen TB, Visser E, Reijntjes MA, et al. One-year stoma-free survival of ileoanal pouches for uc in european centers: The miracle project. Ann Surg Open 2025;6:e596. Conflict of interest: Prof. Holubar, Stefan: No conflict of interest Soop, Mattias: No conflict of interest Poskus, Tomas: No conflict of interest Neary, Peter: No conflict of interest Uchino, Tairin: No conflict of interest Yang, Song-soo: No conflict of interest Adamina, Michel: No conflict of interest Avellaneda, Nicolas Luis: No conflict of interest Barnes, Edward: No conflict of interest Brouquet, Antoine: No conflict of interest Brown, Steven Ross: No conflict of interest De Buck Van Overstraeten, Anthony: No conflict of interest Buskens, Christianne J.: No conflict of interest Chiorean, Michael: No conflict of interest Clark, David: No conflict of interest Cohen, Benjamin: No conflict of interest El Ouali, Sara: No conflict of interest Faiz, Omar Darius: No conflict of interest Fichera, Alessandro: No conflict of interest Hahnloser, Dieter: No conflict of interest Hancock, Laura: No conflict of interest Herfarth, Hans: No conflict of interest Johnston, Michael: No conflict of interest Kayal, Maia: No conflict of interest Laharie, David: No conflict of interest Liberman, Sender: No conflict of interest Loftus, Jr, Edward: No conflict of interest Moeslein, Gabriela: No conflict of interest Myrelid, Pär: No conflict of interest Poylin, Vitaliy: No conflict of interest Qazi, Taha: No conflict of interest Raffals, Laura: No conflict of interest Rubin, David T.: No conflict of interest Spinelli, Antonino: No conflict of interest Steinhagen, Emily: No conflict of interest Tozer, Philip: No conflict of interest Verstockt, Bram: No conflict of interest Warusavitarne, Janindra: No conflict of interest Wexner, Steven: No conflict of interest Winter, Desmond: No conflict of interest
Genetic and Pathological Characteristics of Frontotemporal Dementia with Right Anterior Temporal Predominance: A Multicenter Retrospective Cohort Study
Ulugut, Hülya , Spinelli, Edoardo G., Samancı, Bedia , Santillo, Alexander , Waldö, Maria Landqvist , Riedl, Lina , Stock, Jan Van den, Vandenbulcke, Mathieu, Vandenberghe, Rik, Laforce, Robert, Ducharme, Simon , Pressman, Peter , Tartaglia, Carmela M., Caramelli, Paulo, Souza, Leonardo Cruz de, Takada, Leonel Tadao, Morin, Alexandre , Schroeter, Matthias L, Kim, Eun‐Joo, Moon, So Young, Agosta, Federica, Filippi, Massimo, Gürvit, Hakan, Galimberti, Daniela, Miller, Bruce L., Sturm, Virginia E. , Miyagawa, Toji , Whitwell, Jennifer L., Boeve, Brad F, Rohrer, Jonathan D., Tempini, Maria Luisa Gorno , Josephs, Keith A., Warren, Jason D. , Rankin, Katherine, Group, International rtvFTD Working, Agosta, Federica , Spinelli, Edoardo Gioele , Agosta, Federica , Younes, Kyan , Bertoux, Maxime , Montembeault, Maxime , Fumagalli, Giorgio , Ghirelli, Alma , Jung, Na‐Yeon , Illán‐Gala, Ignacio , Thompson, J. C. , Kobylecki, Christopher , Englund, Elisabet , Stock, Jan Van den , Vandenbulcke, Mathieu , Vandenberghe, Rik , Laforce, Robert , Caramelli, Paulo , Souza, Leonardo Cruz de , Takada, Leonel Tadao , Schroeter, Matthias L , Kim, Eun‐Joo , Moon, So Young , Canu, Elisa , Filippi, Massimo , Gurvit, Hakan I. , Diehl‐Schmid, Janine , Galimberti, Daniela , Lebouvier, Thibaud , Miller, Bruce L. , Whitwell, Jennifer L. , Rohrer, Jonathan D. , Josephs, Keith A. , Snowden, Julie S. , Rankin, Katherine P. , Pijnenburg, Yolande A.L.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S3 | Pages: No page available

10.1002/alz70857_103987 Get It

Abstract Background Frontotemporal dementia (FTD) with right anterior temporal lobe (RATL) predominant atrophy is an emerging area of interest. Recent findings by the International Working Group (IWG) have identified this subtype as having a distinct clinical profile within the FTD spectrum (Ulugut et al., 2024, A&D). However, its genetic and pathological underpinnings remain unexplored in large, multicultural cohorts. Methods Retrospective analyses encompassing clinical, genetic, pathological, and neuroimaging data from 23 IWG sites across 13 countries in Asia, Middle East, Europe, North and South America were conducted. The study included 444 patients with FTD exhibiting predominant RATL atrophy. Results Genetic screening was performed on 51% ( n = 225) of the cohort for at least the major frontotemporal lobar degeneration (FTLD) mutations including microtubule‐associated protein tau ( MAPT ), progranulin ( GRN ), and chromosome 9 open reading frame 72 ( C9orf72 ), or dementia panels encompassing extended sets of genes. Of these, 81% were sporadic, showing negative results for the screened genes and a modified Goldman Score of ≥ 3, indicating a negative family history for dementia. The MAPT mutation was the most common genetic variant, identified in 7% of the screened cases (Figure 1). Pathological confirmation was available for 63 patients. Among the sporadic cases, transactive response DNA‐binding protein 43 type C (TDP‐C) pathology was most prevalent (60%, n = 32), while tau‐MAPT pathology was most common in the genetic cases (38%, n = 16). Fifteen cases did not fit neatly into genetic or sporadic categories, displaying heterogeneous pathologies (Figure 2). At the initial visit, compared to genetic cases, patients with TDP‐C pathology were older, and more frequently exhibited semantic deficits, with less frequent attention difficulties and executive dysfunction. No differences were observed in sex distribution, symptom duration or disease severity between genetic and sporadic TDP‐C cases. However, left handedness was more common in TDP‐C cases (14%) compared to genetic cases (5%). Conclusion While FTD with RATL atrophy primarily appears sporadic, a significant proportion of cases exhibit genetic variants. These sporadic and genetic subtypes display distinct neuropathological features and clinical manifestations. Given the implications for therapeutic strategies, precise clinical and molecular subtyping is critical for enhancing patient management and ensuring appropriate enrollment in clinical trials.
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers
Rimini, Margherita , Antonuzzo, Lorenzo , Kim, Jin Won , Saborowski, Anna , Pressiani, Tiziana , Peeters, Frederik , Pircher, Chiara , Parisi, Alessandro , Chon, Hong Jae , Martirena, A. , Fimkelmeier, Fabian, Perkhofer, Lukas , Pinto, C. , KANG, Beodeul , Pastorino, Alessandro , Rodriquenz, Maria Grazia , Scartozzi, Mario, Zumstein, Lucrezia , Ghidini, Michele , Aprile, Giuseppe , Spinelli, Gian Paolo , Yung‐Yeh, Su, Warmington, Emily , Lancianese, Alessia , Lavacchi, Daniele, Vogel, Arndt, Salani, Francesca , Persano, Mara , Balsano, Rita , Passeri, Laura , Satake, Tomoyuki, Rimassa, Lorenza , Casadei‐Gardini, Andrea , Vogel, Arndt , Rapposelli, Ilario Giovanni , Pircher, Chiara , Castet, Florian , Jae Chon, Hong , Landriscina, Matteo , Fenocchio, Elisabetta , Yoo, Changhoon , Kang, Minsu , Persano, Mara , Niger, Monica , Antonuzzo, Lorenzo , Parisi, Alessandro , Casadei-Gardini, Andrea , Rimassa, Lorenza , Casadei-Gardini, Andrea , Saborowski, Anna , Pressiani, Tiziana , Salani, Francesca , Vogel, Arndt , Rimini, Margherita , Fornaro, Lorenzo , Ikeda, Masafumi , Abidoye, Oluseyi , Lucchetti, Jessica , Nichetti, Federico , Vivaldi, Caterina , Braconi, Chiara , Pinato, David J. , Tamburini, Emiliano , Tamberi, Stefano , Castet, Florian , Verrico, Monica , Couto, Nuno , Lamarca, Angela , Oneda, Ester , Avallone, Antonio , Dell’Aquila, Emanuela , Kim, Il Hwan , Garajova, Ingrid , Kang, Beodeul, Corallo, Salvatore , Farinea, Giovanni , Diana, Anna , Schirripa, Marta , Scartozzi, Mario , Prager, Gerald W. , Chan, Stephen L. , Bekaii‐Saab, Tanios , Lonardi, Sara , Prete, Alessandra Anna , Bozzarelli, Silvia , Masi, Gianluca , Niger, Monica , Camera, Silvia , Ferrara, Michele

Mayo Clinic

Liver International | November 12, 2025 | Volume: 45 | Issue: 12 | Pages: No page available

10.1111/liv.70428 | PMID 41221651 Get It

ABSTRACT Background We recently published the first real‐world multicenter and multi‐institutional study of cisplatin, gemcitabine, and durvalumab in patients with advanced biliary tract cancer (BTC). Here we present an expanded patient cohort with an increased sample size and longer median follow‐up. Methods The study population included patients with advanced BTC, who received cisplatin/gemcitabine plus durvalumab at 55 centers across 12 countries in Europe, the United States, and Asia. The primary endpoints of the study were progression‐free survival (PFS) and overall survival (OS). Secondary endpoints were overall response rate (ORR) and safety. Results Overall, 1358 patients were enrolled. Median PFS was 7.6 months (95% CI: 7.2–8.1), and median OS was 15.6 months (95% CI: 14.8–16.5). ORR was 35.6%, and DCR was 82.7%. Any grade AEs occurred in 1213 patients (89.3%). Grade 3–4 AEs occurred in 597 patients (43.2%). The rate of immune‐related AEs (irAE) was 20.3%. Grade 3–4 irAE occurred in 3.0% of patients. At the multivariate analysis for OS, normal albumin level (HR 0.68, 95% CI 0.57–0.81, p < 0.0001), CEA levels within normal ranges (HR 0.68, 95% CI 0.57–0.82, p < 0.0001), NLR < 3 (HR 0.62, 95% CI 0.52–0.74, p < 0.0001), ECOG PS 0 (HR 0.51, 95% CI 0.42–0.61, p < 0.0001), and prior surgery (HR 0.80, 95% CI 0.65–0.99, p = 0.036) were positive prognostic factors. Conclusion The updated findings, derived from an expanded cohort, further support the adoption of durvalumab in combination with gemcitabine and cisplatin in routine clinical practice, reinforcing the efficacy and safety outcomes demonstrated in the phase III TOPAZ‐1 trial.
Senotherapeutics for metabolic disease and diabetic complications
Chaib, Selim , Suda, Masayoshi , Smith, Ulf , Kirkland, James L. , Chaib, Selim , Suda, Masayoshi , Smith, Ulf , Palmer, Allyson K. , Spinelli, Rosa , Prata, Larissa , Tchkonia, Tamar

Mayo Clinic

Journal of Internal Medicine | November 5, 2025 | Volume: 299 | Issue: 1 | Pages: 2-19

10.1111/joim.70039 | PMID 41189469 Get It

Abstract Metabolic diseases, including obesity, Type 2 diabetes (T2D), and metabolic syndrome, are increasingly prevalent worldwide, driven by sedentary lifestyles, aging populations, and complex genetic and environmental factors. Traditionally understood as disorders of glucose and lipid metabolism, a growing body of evidence now implicates cellular senescence as a central, age‐related contributor to metabolic dysfunction. Senescent cells (SCs) accumulate in key metabolic tissues where they disrupt tissue function through the senescence‐associated secretory phenotype (SASP), a pro‐inflammatory and fibrogenic secretome. SASP factors exacerbate insulin resistance, chronic inflammation, and tissue remodeling, advancing the progression and complications of metabolic diseases. These insights have catalyzed the development of senotherapeutics, a class of interventions that includes senolytics (to eliminate SCs), senomorphics (to suppress SASP), and senosensitizers (to render resistant SCs more vulnerable to clearance). Although preclinical studies show promise, translation into clinical practice faces significant challenges, including identifying reliable biomarkers, understanding SC heterogeneity, and optimizing treatment timing and safety. As research advances, senotherapeutics may offer a transformative approach not only to managing metabolic diseases but also to mitigating associated comorbidities. The recognition that antidiabetic agents already in clinical use can modulate key features of senescence highlights a unique translational opportunity, suggesting that prevention of age‐related metabolic disorders may be achievable with therapies already available in routine clinical practice. Medicine is poised to enter a new era in which targeting cellular senescence could fundamentally reshape the prevention and treatment of age‐related metabolic disorders, offering the potential for improved healthspan and reduced disease burden across the lifespan.
Genetically determined body mass index is associated with diffuse large B‐cell lymphoma in polygenic and Mendelian randomization analyses
Moore, Amy , Teras, Lauren R. , Machiela, Mitchell J. , Arias, Joshua , Monnereau, Alain , Wang, Zhaoming , Vermeulen, Roel , Smedby, Karin E. , Spinelli, John J., Nieters, Alexandra , Bracci, Paige M. , Camp, Nicola J. , Hjalgrim, Henrik, Adami, Hans‐Olov , Albanes, Demetrius, Becker, Nikolaus, Benavente, Yolanda , Clavel, Jacqueline , Curtin, Karen , Ghesquières, Hervé, Glimelius, Bengt, Lan, Qing , Liebow, Mark , McKay, James , Offit, Kenneth, Padoan, Marina, Patel, Alpa V. , Ríboli, Elio , Severson, Richard K., Tinker, Lesley F. , Weinstein, Stephanie J. , Zheng, Tongzhang, Chanock, Stephen J., Rothman, Nathaniel , Berndt, Sonja I. , Teras, Lauren R , Wang, Zhaoming , Vajdic, Claire M , De Vivo, Immaculata , Boffetta, Paolo , Brooks-Wilson, Angela R , Canzian, Federico , Southey, Melissa C , Cerhan, James R , Berndt, Sonja I , Clavel, Jacqueline , Machiela, Mitchell J , Riboli, Elio , Kane, Eleanor , Panagiotou, Orestis A. , Doo, Nicole Wong , Slager, Susan L. , Vajdic, Claire M. , Vijai, Joseph , Giles, Graham G. , Link, Brian K. , Arslan, Alan A. , Salles, Gilles , Cozen, Wendy , Vivo, Immaculata De , Albanes, Demetrius , Bisanzi, Simonetta , Brennan, Paul E. , Brooks‐Wilson, Angela , Canzian, Federico , Conde, Lucía , Cox, David G. , Foretová, Lenka , Glimelius, Bengt , Habermann, Thomas M. , Hofmann, Jonathan N. , Lan, Qing , Lincoln, Anne , Maynadié, Marc , Melbye, Mads , Miligi, Lucia , Milne, Roger L. , Molina, Thierry Jo , Morton, Lindsay M. , North, Kari E. , Offit, Kenneth, Piro, Sara , Purdue, Mark P. , Ravichandran, Vignesh , Southey, Melissa C. , Staines, Anthony , Travis, Ruth C. , Wang, Sophia , Weiderpass, Elisabete , Rothman, Nathaniel , Birmann, Brenda M. , Cerhan, James R.

Mayo Clinic

International Journal of Cancer | September 5, 2025 | Volume: 158 | Issue: 1 | Pages: 45-59

10.1002/ijc.70039 | PMID 40910475 Get It

Abstract Obesity has been associated with non‐Hodgkin lymphoma (NHL), but the evidence is inconclusive. We examined the association between genetically determined adiposity and four common NHL subtypes: diffuse large B‐cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma, using eight genome‐wide association studies of European ancestry ( N = 10,629 cases, 9505 controls) and constructing polygenic scores for body mass index (BMI), waist‐to‐hip ratio (WHR), and waist‐to‐hip ratio adjusted for BMI (WHRadjBMI). Higher genetically determined BMI was associated with an increased risk of DLBCL [odds ratio (OR) per standard deviation (SD) = 1.18, 95% confidence interval (95% CI): 1.05–1.33, p = .005]. This finding was consistent with Mendelian randomization analyses, which demonstrated a similar increased risk of DLBCL with higher genetically determined BMI (OR per SD = 1.12, 95% CI: 1.02–1.23, p = .03). No significant associations were observed with other NHL subtypes. Our study demonstrates a positive link between a genetically determined BMI and an increased risk of DLBCL, providing additional support for increased adiposity as a risk factor for DLBCL.
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population
Prinzi, Federica Lo , Salani, Francesca , Saborowski, Anna , Antonuzzo, Lorenzo , Rossari, Federico , Satake, Tomoyuki, Peeters, Frederik , Pressiani, Tiziana , Kim, Jin Won , Finkelmeier, Fabian , Chiara, Pircher, Chon, Hong Jae , Braconi, Chiara , Qaisar, Aitzaz, Pastorino, Alessandro , Castet, Florian , Parisi, Alessandro , Perkhofer, Lukas , Adeva, Jorge , Spinelli, Gian Paolo , Rodriquenz, Maria Grazia , Leo, Silvana, Alvim, Cecilia Melo, Polito, M.G. , Giacomo, Emanuela Di , Bartalini, L. , Grelli, Giada, Rosa, Antonio De, Lavacchi, Daniele, Ikeda, Masafumi, Dekervel, Jeroen , Balsano, Rita , Tesini, Giulia , Boccaccino, Alessandra , Himmelsbach, Vera, Vogel, Arndt, Rimassa, Lorenza , Casadei‐Gardini, Andrea, Vogel, Arndt , Casadei‐Gardini, Andrea , Rossari, Federico , Prager, Gerald W , Farinea, Giovanni , Niger, Monica , Rimini, Margherita , Antonuzzo, Lorenzo , Lo Prinzi, Federica , Parisi, Alessandro , Casadei-Gardini, Andrea , Finkelmeier, Fabian , Castet, Florian , Adeva, Jorge , Tesini, Giulia , Rimassa, Lorenza , Casadei-Gardini, Andrea , Saborowski, Anna , Pressiani, Tiziana , Jae Chon, Hong , Salani, Francesca , De Rosa, Antonio , Dekervel, Jeroen , Vogel, Arndt , Camera, Silvia , Lucchetti, Jessica , Abidoye, Oluseyi , Rapposelli, Ilario Giovanni , Gallio, Chiara , Tamberi, Stefano , Giordano, Guido , Chiara, Pircher, Tamburini, Emiliano , Yoo, Changhoon , Diana, Anna , Scartozzi, Mario , Prager, Gerald W. , Avallone, Antonio , Schirripa, Marta , Kim, Il Hwan , Oneda, Ester , Verrico, Monica , Couto, Nuno , Chan, Stephen L. , Personeni, Nicola , Garajova, Ingrid , Roque, Ricardo , Ikeda, Masafumi , Niger, Monica , Tonini, Giuseppe , Kang, Minsu , Landriscina, Matteo , Djaballah, Selma Ahcene , Bekaii‐Saab, Tanios , Fornaro, Lorenzo , Masi, Gianluca , Lonardi, Sara , Rimini, Margherita

Mayo Clinic

International Journal of Cancer | July 11, 2025 | Volume: 157 | Issue: 10 | Pages: 2092-2102

10.1002/ijc.70009 | PMID 40641448 Get It

Abstract In recent years, there has been increasing interest in the possible prognostic impact of concomitant medications in patients with cancer treated with immunotherapy combinations. This real‐world analysis aims to evaluate the impact of concomitant medications on survival outcomes in patients with advanced biliary tract cancer (BTCs) treated with cisplatin, gemcitabine and durvalumab (CGD) therapy. The study cohort included patients with a diagnosis of advanced BTCs who were taking concomitant medications for their comorbidities before the start of CGD. The primary objectives were overall survival (OS) and progression‐free survival (PFS). The initial population consisted of 666 patients, who were retrospectively collected from 41 sites in 12 countries. Data on concomitant medications were available for 493 patients. After a median follow‐up of 8.8 months (95% CI: 7.8–9.8), patients who did not take steroids (prednisone >10 mg/day or equivalent) or nonsteroidal anti‐inflammatory drugs (NSAIDs) and opioids, before the start of CGD, had longer OS and PFS in univariate analysis. The multivariate analysis confirmed longer OS for patients who did not take steroids. Patients who did not take steroids had an OS of 14.8 months (95% CI: 13.1–29.1) versus 5.0 months (95% CI: 2.14–11.32) of patients who took prednisone >10 mg/day or equivalent. No differences were reported in terms of overall response rate (ORR), disease control rate (DCR) ( p = 1.0 and p = .16, respectively), and safety profile between the two groups. Our analysis suggests that patients who did not receive steroids before the start of GCD had longer survival and highlighted the relevance of balancing concomitant medications and chemoimmunotherapy.
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population
Prinzi, Federica Lo , Rizzato, Mario Domenico , Saborowski, Anna , Antonuzzo, Lorenzo , Rossari, Federico , Satake, Tomoyuki, Peeters, Frederik , Pressiani, Tiziana , Finkelmeier, Fabian , Braconi, Chiara , Qaisar, Aitzaz, Pirrone, Chiara, Castet, Florian , Parisi, Alessandro , Scartozzi, Mario, Corallo, Salvatore , Perkhofer, Lukas , Adeva, Jorge , Spinelli, Gian Paolo , Rodriquenz, Maria Grazia , Leo, Silvana, Alvim, Cecilia Melo, Roque, Ricardo , Salani, Francesca , Rosa, Antonio De, Lavacchi, Daniele, Dekervel, Jeroen , Niger, Monica, Balsano, Rita , Esposito, Luca, Boccaccino, Alessandra , Himmelsbach, Vera, Zanuso, Valentina , Vogel, Arndt, Rimassa, Lorenza , Casadei‐Gardini, Andrea , Vogel, Arndt , Lo Prinzi, Federica , Rizzato, Mario Domenico , Saborowski, Anna , Antonuzzo, Lorenzo , Rossari, Federico , Peeters, Frederik , Pressiani, Tiziana , Lucchetti, Jessica , Kim, Jin Won , Abidoye, Oluseyi , Rapposelli, Ilario Giovanni , Finkelmeier, Fabian , Giordano, Guido , Nichetti, Federico , Jae Chon, Hong , Qaisar, Aitzaz , Pirrone, Chiara , Castet, Florian , Tamburini, Emiliano , Parisi, Alessandro , Scartozzi, Mario , Avallone, Antonio , Corallo, Salvatore , Schirripa, Marta , Oneda, Ester , Verrico, Monica , Adeva, Jorge , Chan, Stephen L , Spinelli, Gian Paolo , Personeni, Nicola , Garajova, Ingrid , Rodriquenz, Maria Grazia , Roque, Ricardo , Farinea, Giovanni , Salani, Francesca , De Rosa, Antonio , Camera, Silvia , Ikeda, Masafumi , Dekervel, Jeroen , Niger, Monica , Kang, Minsu , Bekaii-Saab, Tanios S , Esposito, Luca , Boccaccino, Alessandra , Djaballah, Selma Ahcene , Zanuso, Valentina , Masi, Gianluca , Vogel, Arndt , Lonardi, Sara , Rimassa, Lorenza , Casadei-Gardini, Andrea , Casadei-Gardini, Andrea , Rimini, Margherita , Fornaro, Lorenzo , Vivaldi, Caterina , Kim, Jin Won , Abidoye, Oluseyi , Tamberi, Stefano , Nichetti, Federico , Chon, Hong Jae , Yoo, Changhoon , Diana, Anna , Prager, Gerald W. , Kim, Il Hwan , Chan, Stephen L. , Ikeda, Masafumi , Niger, Monica , Tonini, Giuseppe , Bekaii‐Saab, Tanios , Landriscina, Matteo , Malapelle, Umberto , Pepe, Francesco , Lonardi, Sara

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 3, 2025 | Volume: 117 | Issue: 10 | Pages: 2029-2043

10.1093/jnci/djaf155 | PMID 40608977 Get It

Abstract Background Cisplatin, gemcitabine, and durvalumab combination is a standard first-line treatment for advanced biliary tract cancer. This study aimed to assess the impact of genetic alterations on outcomes in patients with advanced biliary tract cancer treated with cisplatin, gemcitabine, and durvalumab in real-world clinical practice. Methods Patients with unresectable, locally advanced, or metastatic biliary tract cancer treated with cisplatin and gemcitabine plus durvalumab across 39 centers in 11 countries in Europe, the United States, and Asia were included in this analysis. Results The cohort included 513 patients with advanced biliary tract cancer. The 5 most frequently altered genes were TP53 (22.1%), KRAS (13.7%), CDKN2A/B (13.6%), ARID1A (12.2%), and IDH1 (9.2%). In multivariate analysis, SMAD4 mutations were associated with improved progression-free survival (PFS) (hazard ratio [HR] = 0.49, P = .018) and overall survival (HR = 0.11, P = .023), while TP53 mutations were linked to worse PFS (HR = 1.62, P = .0047) and TERT mutations to worse overall survival (HR = 8.92, P = .0012). No other genomic alterations were statistically associated with outcomes. Subgroup analysis showed that TP53 mutations negatively affected PFS and overall survival in intrahepatic cholangiocarcinoma, while KRAS mutations were associated with poorer PFS in extrahepatic cholangiocarcinoma. No gene alterations were linked to outcomes in gallbladder cancer. Conclusions This large-scale analysis, with comprehensive molecular profiling, supports the positive prognostic impact of SMAD4 mutations for PFS and overall survival and highlights the negative prognostic roles of TP53 (PFS) and TERT (overall survival) mutations, providing valuable insights for personalized treatment strategies in biliary tract cancer.